Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

759 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
HER4 and EGFR Activate Cell Signaling in NRG1 Fusion-Driven Cancers: Implications for HER2-HER3-specific Versus Pan-HER Targeting Strategies.
Udagawa H, Nilsson MB, Robichaux JP, He J, Poteete A, Jiang H, Heeke S, Elamin YY, Shibata Y, Matsumoto S, Yoh K, Okazaki S, Masuko T, Odintsov I, Somwar R, Ladanyi M, Goto K, Heymach JV. Udagawa H, et al. Among authors: ladanyi m. J Thorac Oncol. 2024 Jan;19(1):106-118. doi: 10.1016/j.jtho.2023.08.034. Epub 2023 Sep 9. J Thorac Oncol. 2024. PMID: 37678511 Free PMC article.
Author Correction: Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations.
Miyazaki I, Odintsov I, Ishida K, Lui AJW, Kato M, Suzuki T, Zhang T, Wakayama K, Kurth RI, Cheng R, Fujita H, Delasos L, Vojnic M, Khodos I, Yamada Y, Ishizawa K, Mattar MS, Funabashi K, Chang Q, Ohkubo S, Yano W, Terada R, Giuliano C, Lu YC, Bonifacio A, Kunte S, Davare MA, Cheng EH, de Stanchina E, Lovati E, Iwasawa Y, Ladanyi M, Somwar R. Miyazaki I, et al. Among authors: ladanyi m. Nat Cancer. 2023 Oct;4(10):1526. doi: 10.1038/s43018-023-00663-3. Nat Cancer. 2023. PMID: 37814012 Free PMC article. No abstract available.
Molecular-Based Immunohistochemical Algorithm for Uterine Leiomyosarcoma Diagnosis.
Momeni-Boroujeni A, Yousefi E, Balakrishnan R, Riviere S, Kertowidjojo E, Hensley ML, Ladanyi M, Ellenson LH, Chiang S. Momeni-Boroujeni A, et al. Among authors: ladanyi m. Mod Pathol. 2023 Apr;36(4):100084. doi: 10.1016/j.modpat.2022.100084. Epub 2023 Jan 10. Mod Pathol. 2023. PMID: 36788080 Free PMC article.
Neurofibromatosis Type 2-Yes-Associated Protein and Transcriptional Coactivator With PDZ-Binding Motif Dual Immunohistochemistry Is a Reliable Marker for the Detection of Neurofibromatosis Type 2 Alterations in Diffuse Pleural Mesothelioma.
Li Y, Yang SR, Chen YB, Adusumilli PS, Bialik A, Bodd FM, Ladanyi M, Lopardo J, Offin MD, Rusch VW, Travis WD, Zauderer MG, Chang JC, Sauter JL. Li Y, et al. Among authors: ladanyi m. Mod Pathol. 2023 Mar;36(3):100030. doi: 10.1016/j.modpat.2022.100030. Epub 2023 Jan 10. Mod Pathol. 2023. PMID: 36788094 Free PMC article.
CDKN2A/B mutations and allele-specific alterations stratify survival outcomes in IDH-mutant astrocytomas.
Hickman RA, Gedvilaite E, Ptashkin R, Reiner AS, Cimera R, Nandakumar S, Price A, Vanderbilt C, Fahy T, Young RJ, Miller AM, Mellinghoff IK, Rosenblum MK, Ladanyi M, Arcila ME, Zhang Y, Brannon AR, Bale TA. Hickman RA, et al. Among authors: ladanyi m. Acta Neuropathol. 2023 Dec;146(6):845-847. doi: 10.1007/s00401-023-02639-0. Epub 2023 Oct 13. Acta Neuropathol. 2023. PMID: 37831210 Free PMC article. No abstract available.
Genomic and transcriptomic analysis of a diffuse pleural mesothelioma patient-derived xenograft library.
Offin M, Sauter JL, Tischfield SE, Egger JV, Chavan S, Shah NS, Manoj P, Ventura K, Allaj V, de Stanchina E, Travis W, Ladanyi M, Rimner A, Rusch VW, Adusumilli PS, Poirier JT, Zauderer MG, Rudin CM, Sen T. Offin M, et al. Among authors: ladanyi m. Genome Med. 2022 Nov 15;14(1):127. doi: 10.1186/s13073-022-01129-4. Genome Med. 2022. PMID: 36380343 Free PMC article.
Correlation of Histologic Features with Gene Alterations in Pleural Mesothelioma.
Fanaroff RE, Yang SR, Tan KS, Adusumilli PS, Bodd F, Bowman A, Chang J, Offin MD, Reiner A, Rekhtman N, Rusch VW, Travis WD, Zauderer MG, Ladanyi M, Sauter JL. Fanaroff RE, et al. Among authors: ladanyi m. Mod Pathol. 2025 Jan 7:100706. doi: 10.1016/j.modpat.2025.100706. Online ahead of print. Mod Pathol. 2025. PMID: 39788204 Free article.
759 results